Table 4.
Patients with endoscopic inflammation involvement
| Characteristic | High-risk featuresa N = 71 |
No high-risk features N = 111 |
P value |
|---|---|---|---|
| Duration of symptoms (days, SD) | 41 (106) | 27 (60) | 0.301 |
| IV steroids, n (%) | 41 (66.1) | 42 (58.3) | 0.378 |
| Infliximab/vedolizumab, n (%) | 30 (46.2) | 12 (15.8) | < 0.001 |
| Mean duration from diagnosis to first recurrence (days, SD) | 140 (147) | 144 (121) | 0.902 |
| Outcomes, n (%) | |||
| Hospitalization | 58 (81.7) | 74 (66.7) | 0.028 |
| Duration of hospitalization (days, SD) | 9 (8) | 6 (5) | 0.016 |
| ICU admission | 3 (4.2) | 4 (3.6) | 0.656 |
| Recurrence | 20 (28.2) | 31 (27.9) | 1.000 |
| Repeat endoscopy | 18 (25.4) | 18 (16.2) | 0.181 |
aHigh-risk endoscopic features; deep ulcers > 2 mm in depth, large ulcers > 1 cm, extensive involvement